Opella, Sanofi
Sanofi is scheduled to report results for the third quarter on Friday. Here is what you need to know. BUSINESS OPERATING PROFIT FORECAST: The French pharmaceutical company is expected to make 4.03 ...
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza ...
Wyoming’s attorney general, through a settlement with a French multinational pharmaceutical and healthcare company, has ...
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement ...
Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...
Wyoming’s attorney general, through a settlement with a French multinational pharmaceutical and health care company, has ...
Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of ...
Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business ...
The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback